Early low-calorie and low-protein nutrition in critically ill patients with shock does not worsen renal outcomes compared to standard feeding, per NUTRIREA-3 post hoc analysis.
In a phase 2 randomized trial, OCE-205 improved HRS-AKI in more patients than placebo and showed no excess ischemic or respiratory toxicity, but the study was underpowered after early termination.
A 14-year cohort study of 3,079 individuals with type 1 diabetes reveals that visit-to-visit blood pressure variability, particularly systolic blood pressure variability measured by average real variability, significantly predicts diabetic kidney disease progression. African Caribbean ethnicity emerged as an independent risk factor, with a 54% increased hazard per unit increase in systolic BP variability.
This review synthesizes recent evidence on the massive scale of CKM medication eligibility in the US, the synergistic effects of pharmacotherapy with lifestyle, and emerging neuropsychiatric benefits of GLP-1 receptor agonists.
A longitudinal study using Latent Class Analysis identifies four distinct phenotypes of T2D patients developing CKD, highlighting young-onset and middle-aged low-comorbidity groups as primary drivers of healthcare costs.
This review analyzes a latent class trajectory study identifying four clinical phenotypes of T2D-related CKD, revealing that young-onset patients incur the highest longitudinal healthcare costs.
This review synthesizes evidence comparing SGLT2 inhibitors and GLP-1 receptor agonists, highlighting a significant reduction in chronic kidney disease and acute kidney injury risks associated with SGLT2i initiation.
A large-scale retrospective study in Ontario indicates that solid-organ transplant recipients, particularly kidney transplant patients, experience significantly better outcomes for emergency general surgery conditions when treated at specialized transplant centers compared to academic or community hospitals.
This study evaluates HbA1c, glycated albumin, and fructosamine against CGM in dialysis patients. While HbA1c and glycated albumin show strong correlations with mean glucose, significant clinical biases from ESA use, BMI, and dialysis modality necessitate cautious, individualized interpretation in clinical practice.
A landmark 35-year analysis of DCCT/EDIC data demonstrates that a reduced estimated glomerular filtration rate (30–90 mL/min/1.73 m2) is not an independent risk factor for diabetic ketoacidosis, providing a clearer safety framework for the use of SGLT inhibitors in type 1 diabetes.
A multicenter study of 680 Fabry disease patients reveals that age, renal function, QRS duration, and left ventricular mass are critical independent predictors of major adverse cardiovascular events, highlighting persistent unmet needs despite available disease-specific therapies.
A post hoc analysis of the CRHCP trial demonstrates that intensive blood pressure control (<130/80 mmHg) significantly reduces major adverse
**Confirming JSON Structure**
I'm now fully focused on creating the JSON object. I've re-reviewed both schemas, and am following the most up-to-date and complete instructions. I'm double-checking the required fields, especially `thumbnail`, `lang`, and `multilang`, to ensure the final output is perfectly structured and valid.
cardiovascular events across CKM syndrome stages 2 through 4, providing a favorable net clinical benefit despite an increased risk of hypotension.
The Phase 3 VISIONARY trial interim analysis demonstrates that sibeprenlimab, a monoclonal antibody targeting APRIL, significantly reduces proteinuria and pathogenic IgA1 in patients with IgA nephropathy, offering a promising upstream therapeutic approach with a favorable safety profile.
A phase 1-2 trial shows that autologous hematopoietic stem-cell gene therapy (CTNS-RD-04) safely reduces lysosomal cystine levels in patients with cystinosis, potentially offering a definitive alternative to lifelong cysteamine therapy.
A Phase 2 trial of BI 764198, a selective TRPC6 inhibitor, demonstrates significant proteinuria reduction in patients with focal segmental glomerulosclerosis. This study provides the first clinical evidence for podocyte-targeted therapy, marking a potential shift in the management of progressive proteinuric kidney diseases.
A large-scale meta-analysis reveals that SGLT2 inhibitors significantly reduce kidney disease progression, AKI, and hospitalizations in patients with CKD, independent of diabetes status or baseline albuminuria.
A meta-analysis of over 70,000 participants confirms that SGLT2 inhibitors significantly reduce chronic kidney disease progression regardless of baseline kidney function or albuminuria levels, supporting their use even in patients with Stage 4 CKD or minimal protein excretion.
The LIBERATE-D randomized trial suggests that a conservative, indication-driven dialysis strategy may enhance kidney recovery and reduce treatment burden in stable patients with dialysis-requiring acute kidney injury compared to conventional thrice-weekly dialysis.
A large-scale prospective study from the UK Biobank reveals that a comprehensive Mediterranean lifestyle—integrating diet, physical activity, and social connectivity—significantly reduces the risk of incident chronic kidney disease by up to 35%.
